IP Library Granted Patent US 10,806,733
Granted Patent B2
US 10,806,733 · App. 16/017,248 · Granted Oct 20, 2020

Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation

Inventors: Brian Metcalf (South San Francisco, CA); Chihyuan Chuang (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
A61K31/4985A61K31/192A61K31/235A61K31/41A61K31/416A61K31/437A61K31/445A61K31/4406A61K31/4439A61K31/47C07C65/30C07C69/76C07D211/62C07D213/30C07D213/80C07D215/14C07D231/56C07D257/04C07D401/04C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,733
App. No.
16/017,248
Granted
Oct 20, 2020
Kind
B2
Abstract

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Claims (17)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

Q is a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl, each of which is substituted with one R a ;

R 2 , R 3 , and R 4 are each hydrogen;

Y is CH 2 ;

X is O or CH 2 ;

R 5 is halo or OH;

R 6 and R 7 together form oxo;

R a is heteroaryl substituted with one to three R c ; and

each R c is independently selected from the group consisting of C 1-8 alkyl and haloC 1-8 alkyl.

2. The compound of claim 1 , wherein X is 0.

3. The compound of claim 1 , wherein R 5 is OH.

4. The compound of claim 1 , wherein R a is substituted with one R c , and R c is C 1-6 alkyl or haloC 1-6 alkyl.

5. The compound of claim 2 , wherein:

Q is pyridin-3-yl substituted with one R a .

6. The compound of claim 5 , wherein R a is heteroaryl having two nitrogen ring atoms.

7. The compound of claim 6 , wherein R a is substituted with one R c , and R c is C 1-6 alkyl or haloC 1-6 alkyl.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2020
From: CHUANG, CHIHYUAN
To: CYTOKINETICS, INC.
Reel/Frame 052355/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2020
From: CYTOKINETICS, INC.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 052355/0408 →
CONFIRMATION ASSIGNMENT Recorded Apr 9, 2020
From: CYTOKINETICS, INC.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 052355/0876 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2019
From: METCALF, BRIAN
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 048382/0583 →
Continuity (6)
Continuation 15852406 · Dec 22, 2017
Continuation 14662156 · Mar 18, 2015
Continuation 13730674 · Dec 28, 2012
Provisional Application 61661320 · Jun 18, 2012
Provisional Application 61581053 · Dec 28, 2011
Related Publication 20190160060A1 · May 30, 2019
Cited By (1)
US 12,479,816